Allmed Medical Products Co Ltd Class A

Allmed Medical released its 2026 interim report. Total operating revenue was 1.839 billion yuan, and net profit attributable to the parent company was 194 million yuan, a decrease of 6.3152 million yuan from the same period last year, down 3.16% year-on-year. Net cash flow from operating activities was negative 40.8978 million yuan, a decrease of 386 million yuan from the same period last year, down 111.85% year-on-year. The company's asset-liability ratio was 39.38%, gross margin was 31.20%, and ROE was 5.24%, all showing varying degrees of change. The number of shareholders was 38,800, and the top ten shareholders held 66.20% of the total share capital.

Allmed Medical released its 2026 interim report, with attributable net profit for the first half at 194 million yuan, down 3.2% year on year. Operating revenue was 1.839 billion yuan, up 9.7% year on year. Attributable net profit excluding non-recurring items was 191 million yuan, up 2.9% year on year. Net operating cash flow was negative 40.9 million yuan, down 111.9% year on year. In the second quarter, operating revenue was 942 million yuan, up 2.7% year on year, while attributable net profit was 84.57 million yuan, down 25.4% year on year. The company flagged risks including a high share of export revenue, raw material price fluctuations, and exchange rate volatility. However, domestic revenue rose 17.99% year on year, cross-border e-commerce revenue measured in US dollars grew 67% year on year, and sales of high-margin products such as hygiene care products and advanced wound dressings increased 91.97% and 13.90% respectively.

Allmed Medical responded during an earnings briefing to the matter of CFO Huang Tiezhu joining Guangxi Liugong as head of finance just four days after his departure, stating that he resigned from the company for personal family reasons, and did not provide further explanation regarding investor questions about potential business disagreements. The company also addressed the long-term decline in its share price, noting that although first-quarter 2026 revenue grew 18.12% year-on-year and net profit attributable to the parent rose 25.95%, secondary market prices are influenced by multiple factors, and earnings growth does not necessarily drive market value higher. It will consider measures such as industry chain-related mergers and acquisitions at an appropriate time in the future. In addition, the company terminated a 66 million yuan land transfer deal, and the reclaimed land will be for its own use. This termination does not constitute a prior-period accounting error, and the related gains or losses will be recorded in the 2026 current period. Construction of the Indonesian factory is progressing normally and is still in the construction phase.